{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:35:05Z","timestamp":1757619305202,"version":"3.44.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NRF","award":["RS-2024-00357857"],"award-info":[{"award-number":["RS-2024-00357857"]}]},{"DOI":"10.13039\/100020206","name":"Korea Dementia Research Center","doi-asserted-by":"publisher","award":["RS-2024-00343370"],"award-info":[{"award-number":["RS-2024-00343370"]}],"id":[{"id":"10.13039\/100020206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018749","name":"KBRI","doi-asserted-by":"crossref","award":["25-BR-02-04 and 25-BR-05-01, 25-BR-06-01"],"award-info":[{"award-number":["25-BR-02-04 and 25-BR-05-01, 25-BR-06-01"]}],"id":[{"id":"10.13039\/100018749","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003665","name":"NIPA","doi-asserted-by":"crossref","award":["H0501-25-1001"],"award-info":[{"award-number":["H0501-25-1001"]}],"id":[{"id":"10.13039\/501100003665","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Brain"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We previously demonstrated that ibrutinib has therapeutic efficacy against AD pathologies when injected intraperitoneally at a lower dosage (10\u00a0mg\/kg, daily for 2 weeks) or orally at a higher dosage (30\u00a0mg\/kg, daily for 1 month) in AD mice models. However, the effect of chronic lower dose of ibrutinib by oral administration on AD pathologies has not been investigated yet. Therefore, we investigated whether long-term oral administration of ibrutinib at a lower dose (1 or 10\u00a0mg\/kg, daily for 5 months) on AD pathology and in vivo toxicity in 5xFAD mice. We found ibrutinib enhanced cognitive function and alleviated A\u03b2 pathology in 5xFAD mice without hepatotoxicity. Furthermore, ibrutinib-treated 5xFAD mice decrease tau hyperphosphorylation, p-GSK3\u03b1\/\u03b2 levels, and markers of neuroinflammation such as Iba-1, GFAP, and NLRP3. Collectively, these translational studies indicate chronic oral administration of ibrutinib at low doses improves cognitive function and suppresses AD pathology\/neuroinflammation in an AD mice model thereby having potential as an effective multitarget AD therapeutic in clinical application.<\/jats:p>","DOI":"10.1186\/s13041-025-01225-7","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T07:10:08Z","timestamp":1753168208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronic oral administration of ibrutinib prevents long-term memory deficits and reduces AD pathology and neuroinflammatory responses in a mouse model of AD"],"prefix":"10.1186","volume":"18","author":[{"given":"Hyun-ju","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sora","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoo Joo","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-Woo","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan-Hu","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Mi","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seokjun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Yeong","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyang-Sook","family":"Hoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"issue":"1","key":"1225_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW. The neuropathological diagnosis of alzheimer\u2019s disease. Mol Neurodegeneration. 2019;14(1):32.","journal-title":"Mol Neurodegeneration"},{"issue":"3","key":"1225_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"F Leng","year":"2021","unstructured":"Leng F, Edison P. Neuroinflammation and microglial activation in alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17(3):157\u201372.","journal-title":"Nat Rev Neurol"},{"key":"1225_CR3","doi-asserted-by":"crossref","unstructured":"Lee HJ, Choi HJ, Jeong YJ, Na YH, Hong JT, Han JM, Hoe HS, Lim KH. Developing theragnostics for Alzheimer\u2019s disease: Insights from cancer treatment. Int J Biol Macromol 2024:131925.","DOI":"10.1016\/j.ijbiomac.2024.131925"},{"issue":"1","key":"1225_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13041-020-00673-7","volume":"13","author":"SG Jeon","year":"2020","unstructured":"Jeon SG, Lee HJ, Park H, Han KM, Hoe HS. The VEGF inhibitor vatalanib regulates AD pathology in 5xFAD mice. Mol Brain. 2020;13(1):131.","journal-title":"Mol Brain"},{"key":"1225_CR5","doi-asserted-by":"publisher","first-page":"106725","DOI":"10.1016\/j.phrs.2023.106725","volume":"190","author":"HJ Lee","year":"2023","unstructured":"Lee HJ, Hoe HS. Inhibition of CDK4\/6 regulates AD pathology, neuroinflammation and cognitive function through DYRK1A\/STAT3 signaling. Pharmacol Res. 2023;190:106725.","journal-title":"Pharmacol Res"},{"issue":"3","key":"1225_CR6","doi-asserted-by":"publisher","first-page":"e13332","DOI":"10.1111\/acel.13332","volume":"20","author":"HJ Lee","year":"2021","unstructured":"Lee HJ, Jeon SG, Kim J, Kang RJ, Kim SM, Han KM, Park H, Kim KT, Sung YM, Nam HY, et al. Ibrutinib modulates abeta\/tau pathology, neuroinflammation, and cognitive function in mouse models of alzheimer\u2019s disease. Aging Cell. 2021;20(3):e13332.","journal-title":"Aging Cell"},{"issue":"1","key":"1225_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13041-023-01051-9","volume":"16","author":"HJ Lee","year":"2023","unstructured":"Lee HJ, Hwang JW, Park JH, Jeong YJ, Jang JY, Hoe HS. Profiling tyrosine kinase inhibitors as AD therapeutics in a mouse model of AD. Mol Brain. 2023;16(1):63.","journal-title":"Mol Brain"},{"issue":"1","key":"1225_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13195-021-00831-6","volume":"13","author":"A Ancidoni","year":"2021","unstructured":"Ancidoni A, Bacigalupo I, Remoli G, Lacorte E, Piscopo P, Sarti G, Corbo M, Vanacore N, Canevelli M. Anticancer drugs repurposed for alzheimer\u2019s disease: a systematic review. Alzheimers Res Ther. 2021;13(1):96.","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"1225_CR9","first-page":"CD001190","volume":"6","author":"JS Birks","year":"2018","unstructured":"Birks JS, Harvey RJ. Donepezil for dementia due to alzheimer\u2019s disease. Cochrane Database Syst Rev. 2018;6(6):CD001190.","journal-title":"Cochrane Database Syst Rev"},{"issue":"14","key":"1225_CR10","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","volume":"348","author":"B Reisberg","year":"2003","unstructured":"Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, Memantine Study G. Memantine in moderate-to-severe alzheimer\u2019s disease. N Engl J Med. 2003;348(14):1333\u201341.","journal-title":"N Engl J Med"},{"issue":"3","key":"1225_CR11","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s11481-019-09839-0","volume":"14","author":"J Keaney","year":"2019","unstructured":"Keaney J, Gasser J, Gillet G, Scholz D, Kadiu I. Inhibition of bruton\u2019s tyrosine kinase modulates microglial phagocytosis: therapeutic implications for alzheimer\u2019s disease. J Neuroimmune Pharmacol. 2019;14(3):448\u201361.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"1","key":"1225_CR12","doi-asserted-by":"publisher","first-page":"e13079","DOI":"10.1111\/acel.13079","volume":"19","author":"AE Ekpenyong-Akiba","year":"2020","unstructured":"Ekpenyong-Akiba AE, Poblocka M, Althubiti M, Rada M, Jurk D, Germano S, Kocsis-Fodor G, Shi Y, Canales JJ, Macip S. Amelioration of age-related brain function decline by bruton\u2019s tyrosine kinase Inhibition. Aging Cell. 2020;19(1):e13079.","journal-title":"Aging Cell"},{"issue":"15","key":"1225_CR13","doi-asserted-by":"publisher","first-page":"E3129","DOI":"10.1073\/pnas.1618804114","volume":"114","author":"BJ Wang","year":"2017","unstructured":"Wang BJ, Her GM, Hu MK, Chen YW, Tung YT, Wu PY, Hsu WM, Lee H, Jin LW, Hwang SL, et al. ErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2017;114(15):E3129\u201338.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1225_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/alzrt272","volume":"6","author":"WF Goure","year":"2014","unstructured":"Goure WF, Krafft GA, Jerecic J, Hefti F. Targeting the proper amyloid-beta neuronal toxins: a path forward for alzheimer\u2019s disease immunotherapeutics. Alzheimers Res Ther. 2014;6(4):42.","journal-title":"Alzheimers Res Ther"},{"key":"1225_CR15","doi-asserted-by":"publisher","first-page":"795375","DOI":"10.1155\/2014\/795375","volume":"2014","author":"P Carrillo-Mora","year":"2014","unstructured":"Carrillo-Mora P, Luna R, Col\u00edn-Barenque L. Amyloid beta: multiple mechanisms of toxicity and only some protective effects?? Oxidative Med Cell Longev. 2014;2014:795375.","journal-title":"Oxidative Med Cell Longev"},{"issue":"9","key":"1225_CR16","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/aps.2017.28","volume":"38","author":"G-f Chen","year":"2017","unstructured":"Chen G-f, Xu T-h, Yan Y, Zhou Y-r, Jiang Y, Melcher K, Xu HE. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. 2017;38(9):1205\u201335.","journal-title":"Acta Pharmacol Sin"},{"issue":"6","key":"1225_CR17","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","volume":"104","author":"C Hooper","year":"2008","unstructured":"Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of alzheimer\u2019s disease. J Neurochem. 2008;104(6):1433\u20139.","journal-title":"J Neurochem"},{"key":"1225_CR18","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.3233\/JAD-2012-129025","volume":"33","author":"F Hernandez","year":"2013","unstructured":"Hernandez F, Lucas JJ, Avila J. GSK3 and tau: two convergence points in alzheimer\u2019s disease. J Alzheimers Dis. 2013;33:S141\u20134.","journal-title":"J Alzheimers Dis"},{"issue":"17","key":"1225_CR19","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.2174\/1568026620666200516153136","volume":"20","author":"P Wadhwa","year":"2020","unstructured":"Wadhwa P, Jain P, Jadhav HR. Glycogen synthase kinase 3 (GSK3): its role and inhibitors. Curr Top Med Chem. 2020;20(17):1522\u201334.","journal-title":"Curr Top Med Chem"},{"key":"1225_CR20","doi-asserted-by":"publisher","first-page":"101791","DOI":"10.1016\/j.arr.2022.101791","volume":"83","author":"PK Jayaswamy","year":"2023","unstructured":"Jayaswamy PK, Vijaykrishnaraj M, Patil P, Alexander LM, Kellarai A, Shetty P. Implicative role of epidermal growth factor receptor and its associated signaling partners in the pathogenesis of alzheimer\u2019s disease. Ageing Res Rev. 2023;83:101791.","journal-title":"Ageing Res Rev"},{"issue":"41","key":"1225_CR21","doi-asserted-by":"publisher","first-page":"16743","DOI":"10.1073\/pnas.1208011109","volume":"109","author":"L Wang","year":"2012","unstructured":"Wang L, Chiang HC, Wu W, Liang B, Xie Z, Yao X, Ma W, Du S, Zhong Y. Epidermal growth factor receptor is a preferred target for treating amyloid-beta-induced memory loss. Proc Natl Acad Sci U S A. 2012;109(41):16743\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1225_CR22","doi-asserted-by":"publisher","first-page":"e13332","DOI":"10.1111\/acel.13332","volume":"20","author":"H-j Lee","year":"2021","unstructured":"Lee H-j, Jeon SG, Kim J, Kang RJ, Kim S-M, Han K-M, Park H, Kim K-t, Sung YM, Nam HY, et al. Ibrutinib modulates A\u03b2\/tau pathology, neuroinflammation, and cognitive function in mouse models of alzheimer\u2019s disease. Aging Cell. 2021;20(3):e13332.","journal-title":"Aging Cell"},{"issue":"8","key":"1225_CR23","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1248\/bpb.b21-01057","volume":"45","author":"H Chen","year":"2022","unstructured":"Chen H, Shen Y, Liang Y, Qiu Y, Xu M, Li C. Selexipag improves Lipopolysaccharide-Induced ARDS on C57BL\/6 mice by modulating the cAMP\/PKA and cAMP\/Epac1 signaling pathways. Biol Pharm Bull. 2022;45(8):1043\u201352.","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"1225_CR24","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1021\/acschemneuro.1c00831","volume":"13","author":"M Haseeb","year":"2022","unstructured":"Haseeb M, Javaid N, Yasmeen F, Jeong U, Han JH, Yoon J, Seo JY, Heo JK, Shin HC, Kim MS, et al. Novel Small-Molecule inhibitor of NLRP3 inflammasome reverses cognitive impairment in an alzheimer\u2019s disease model. ACS Chem Neurosci. 2022;13(6):818\u201333.","journal-title":"ACS Chem Neurosci"},{"issue":"50","key":"1225_CR25","doi-asserted-by":"publisher","first-page":"32145","DOI":"10.1073\/pnas.2009680117","volume":"117","author":"N Lonnemann","year":"2020","unstructured":"Lonnemann N, Hosseini S, Marchetti C, Skouras DB, Stefanoni D, D\u2019Alessandro A, Dinarello CA, Korte M. The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2020;117(50):32145\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1225_CR26","doi-asserted-by":"publisher","first-page":"701282","DOI":"10.3389\/fimmu.2021.701282","volume":"12","author":"H Bai","year":"2021","unstructured":"Bai H, Zhang Q. Activation of NLRP3 inflammasome and onset of alzheimer\u2019s disease. Front Immunol. 2021;12:701282.","journal-title":"Front Immunol"},{"key":"1225_CR27","doi-asserted-by":"publisher","first-page":"7360","DOI":"10.1038\/ncomms8360","volume":"6","author":"M Ito","year":"2015","unstructured":"Ito M, Shichita T, Okada M, Komine R, Noguchi Y, Yoshimura A, Morita R. Bruton\u2019s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. Nat Commun. 2015;6:7360.","journal-title":"Nat Commun"}],"container-title":["Molecular Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-025-01225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13041-025-01225-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-025-01225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T17:19:19Z","timestamp":1757265559000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularbrain.biomedcentral.com\/articles\/10.1186\/s13041-025-01225-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1225"],"URL":"https:\/\/doi.org\/10.1186\/s13041-025-01225-7","relation":{},"ISSN":["1756-6606"],"issn-type":[{"type":"electronic","value":"1756-6606"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures were approved by the institutional biosafety committee (IBC) and were performed in accordance with approved animal protocols and guidelines of the Korea Brain Research Institute (KBRI, approval nos. IACUC-19-00049 and IACUC-23-00020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}